Technology area: Biotechnology & Pharmaceuticals
22 pending office actions • 15 art units • 21 examiners • 0 of 22 (0%) have an AI response strategy ready • 17 patents granted in the last 365 days
The Children's Hospital of Philadelphia has 25 pending office actions in Biotechnology & Pharmaceuticals. The matters span 23 distinct examiners and 17 distinct art units, making the portfolio broadly distributed while also showing repeated assignments within both examination dimensions. The lower examiner and art-unit counts than the office-action count indicate that some examiners and art units handle multiple matters.
MYERS, CARLA J is the busiest examiner, with 2 pending matters. This is the only examiner-level concentration identified in the profile, but it gives counsel a defined opportunity to compare those matters for shared issues, disclosure support, and response strategy.
The scale and distribution favor centralized docket management combined with matter-specific prosecution analysis. Counsel should preserve consistent positions across related technical areas, while adapting claim amendments and arguments to each examiner and art-unit setting.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (14%) |
| §103 only | 5 (23%) |
| §112 only | 3 (14%) |
| Double-patenting + other | 3 (14%) |
| Multi-statute (no §101) | 8 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MYERS, CARLA J | 2 | 49.5% | +46.0% |
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
| PARK, HAEJIN S | 1 | 55.1% | +38.3% |
| OLSON, ANDREA STEFFEL | 1 | 62.4% | -11.9% |
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
| MATTHEWS, CHRISTINE HOPKINS | 1 | 71.8% | +31.4% |
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
| HUDSON, AMY ROSE | 1 | 74.8% | +11.7% |
| CRAIGO, WILLIAM A | 1 | 48.9% | +38.1% |
| VOKES, KATHLEEN PAIGE | 1 | 56.3% | +27.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18820706 | FASORACETAM CRYSTALLINE FORMS | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033627 | COMPOSITIONS AND METHODS FOR IN VIVO GENE TRANSFER | SHIN, DANA H | 37d overdue |
| 18713342 | FLAVANOID CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | OLSON, ANDREA STEFFEL | — |
| 18497386 | METHODS OF DIAGNOSING AND TREATING CONDUCT DISORDER | KOSAR, ANDREW D | — |
| 18557664 | TRANSFER TRAY AND PRIMING CART FOR NEONATAL CANNULATION AND RELATED METHODS | MATTHEWS, CHRISTINE HOPKINS | — |
| 18557033 | ADENO-ASSOCIATED VIRAL VECTORS FOR TRANSDUCTION OF COCHLEA | MATALKAH, FATIMAH KHALAF | — |
| 18287150 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF H-ABC LEUKODYSTROPHY | HUDSON, AMY ROSE | — |
| 18282653 | ENEMA ASSIST DEVICE | VOKES, KATHLEEN PAIGE | — |
| 18550070 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF BONE MARROW FAILURE DISEASES ASSOCIATED WITH RIBOSOMOPATHIES | PERSONS, JENNA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18766315 | METHODS OF IMPROVING MYOCARDIAL PERFORMANCE IN FONTAN PATIENTS USING UDENAFIL COMPOSITIONS | PARK, HAEJIN S | — |
| 18497386 | METHODS OF DIAGNOSING AND TREATING CONDUCT DISORDER | KOSAR, ANDREW D | — |
| 18557664 | TRANSFER TRAY AND PRIMING CART FOR NEONATAL CANNULATION AND RELATED METHODS | MATTHEWS, CHRISTINE HOPKINS | — |
| 18557033 | ADENO-ASSOCIATED VIRAL VECTORS FOR TRANSDUCTION OF COCHLEA | MATALKAH, FATIMAH KHALAF | — |
| 18287150 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF H-ABC LEUKODYSTROPHY | HUDSON, AMY ROSE | — |
| 18553893 | ANTIMICROBIAL ELUTING AIRWAY DEVICES | CRAIGO, WILLIAM A | — |
| 18282653 | ENEMA ASSIST DEVICE | VOKES, KATHLEEN PAIGE | — |
| 18044471 | GENETIC ALTERATIONS ASSOCIATED WITH EOSINOPHILIC ESOPHAGITIS AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF DISEASE | MYERS, CARLA J | — |
| Art Unit | Apps |
|---|---|
| 1635 | 3 |
| 1693 | 2 |
| 3791 | 2 |
| 1636 | 2 |
| 1682 | 2 |
| 1656 | 2 |
| 1621 | 1 |
| 1614 | 1 |
| 1625 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18820706 | FASORACETAM CRYSTALLINE FORMS | AULAKH, CHARANJIT | 1621 | §102§103§112DP | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18766315 | METHODS OF IMPROVING MYOCARDIAL PERFORMANCE IN FONTAN PATIENTS USING UDENAFIL COMPOSITIONS | PARK, HAEJIN S | 1614 | §112DP | Non-Final OA | — | Pending | Jul 08, 2024 |
| 18713342 | FLAVANOID CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | OLSON, ANDREA STEFFEL | 1693 | §101§102§103§112DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18497386 | METHODS OF DIAGNOSING AND TREATING CONDUCT DISORDER | KOSAR, ANDREW D | 1625 | §103§112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18557664 | TRANSFER TRAY AND PRIMING CART FOR NEONATAL CANNULATION AND RELATED METHODS | MATTHEWS, CHRISTINE HOPKINS | 3791 | §102§103§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18557033 | ADENO-ASSOCIATED VIRAL VECTORS FOR TRANSDUCTION OF COCHLEA | MATALKAH, FATIMAH KHALAF | 1638 | §103§112 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18287150 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF H-ABC LEUKODYSTROPHY | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Oct 16, 2023 |
| 18553893 | ANTIMICROBIAL ELUTING AIRWAY DEVICES | CRAIGO, WILLIAM A | 1615 | §103 | Final Rejection | — | Pending | Oct 04, 2023 |
| 18282653 | ENEMA ASSIST DEVICE | VOKES, KATHLEEN PAIGE | 3783 | §102§103 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18550070 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF BONE MARROW FAILURE DISEASES ASSOCIATED WITH RIBOSOMOPATHIES | PERSONS, JENNA L | 1637 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18251075 | BREATH BIOMARKERS OF SARS-COV-2 IN CHILDREN AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF COVID-19 | WEARE, MEREDITH H | 3791 | §101§103 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18033627 | COMPOSITIONS AND METHODS FOR IN VIVO GENE TRANSFER | SHIN, DANA H | 1635 | §102§112 | Final Rejection | 37d overdue | Pending | Apr 25, 2023 |
| 18044471 | GENETIC ALTERATIONS ASSOCIATED WITH EOSINOPHILIC ESOPHAGITIS AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF DISEASE | MYERS, CARLA J | 1682 | §112 | Non-Final OA | — | Pending | Mar 08, 2023 |
| 18176546 | Compositions and Methods for Modulating Factor IX Function | TSAY, MARSHA M | 1656 | §103 | Non-Final OA | 73d overdue | Pending | Mar 01, 2023 |
| 18007407 | NOVEL THERAPEUTIC USES OF COMPOUNDS FOR ENHANCING MITOCHONDRIAL FUNCTION AND TREATING MITOCHONDRIAL DISEASES | CHO, DAVID H | 1693 | §103Other | Final Rejection | 12d | Pending | Jan 30, 2023 |
| 18006975 | IN UTERO AND POSTNATAL GENE EDITING AND THERAPY FOR TREATMENT OF MONOGENIC DISEASES, INCLUDING MUCOPOLYSACCHARIDOSIS TYPE 1H AND OTHER DISORDERS | MCLEOD, AFRICA MHAIRIE | 1635 | §102§103§112 | Non-Final OA | — | Pending | Jan 26, 2023 |
| 17777245 | COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION | MCKNIGHT, CIARA A | 1656 | §103DP | Non-Final OA | — | Pending | May 16, 2022 |
| 17694841 | Viral Vectors for Prophylaxis and Therapy of Hemoglobinopathies | MARVICH, MARIA | 1634 | §112 | Non-Final OA | — | Pending | Mar 15, 2022 |
| 17641502 | COMPOSITIONS COMPRISING RARE GENETIC SEQUENCE VARIANTS ASSOCIATED WITH PULMONARY FUNCTION AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF ASTHMA IN AFRICAN AMERICAN PATIENTS | MYERS, CARLA J | 1682 | §112 | Non-Final OA | — | Pending | Mar 09, 2022 |
| 17279542 | 2' FANA MODIFIED FOXP3 ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112 | Non-Final OA | — | Pending | Mar 24, 2021 |
| 17272005 | SCALABLE TAGGING OF ENDOGENOUS GENES BY HOMOLOGY-INDEPENDENT INTRON TARGETING | REGA, KYLE THOMAS | 1636 | §103 | Final Rejection | 16d | Pending | Feb 26, 2021 |
| 16344298 | GENE TRANSFER COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEGENERATIVE DISEASES | FONTAINHAS, AURORA M | 1675 | §103Other | Final Rejection | — | Pending | Apr 23, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Children's Hospital of Philadelphia has 22 pending office actions as of October 2026, spread across 15 art units and 21 examiners.
Carla J Myers has the most, with 2 of The Children's Hospital of Philadelphia's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
